Trevi Therapeutics (TRVI) Assets (2018 - 2026)

Trevi Therapeutics' Assets history runs 9 years deep, the most recent figure standing at $179.6 million for Q1 2026.

• In Q1 2026, Assets rose 67.85% year-over-year to $179.6 million; the TTM figure through Mar 2026 stood at $179.6 million (up 67.85% YoY), while the FY2025 annual figure was $193.4 million, up 74.43% from the prior year.
• Assets was $179.6 million for Q1 2026 at Trevi Therapeutics, down from $193.4 million in the prior quarter.
• In the past five years, Assets ranged from a high of $208.3 million in Q2 2025 to a low of $30.4 million in Q1 2022.
• Historically, Assets has averaged $116.8 million across 5 years, with a median of $107.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Assets jumped 306.26% in 2022, then tumbled 32.4% in 2024.
• A 5-year view of Assets shows it stood at $123.0 million in 2022, then declined by 27.32% to $89.4 million in 2023, then rose by 24.05% to $110.9 million in 2024, then surged by 74.43% to $193.4 million in 2025, then retreated by 7.15% to $179.6 million in 2026.
• The last three Assets figures came in at $179.6 million (Q1 2026), $193.4 million (Q4 2025), and $199.4 million (Q3 2025), per Business Quant data.